Register now for the Know All Your Treatment Options webinar, produced and moderated by the End Brain Cancer Initiative (EBCI).
Register now for the Know All Your Treatment Options webinar, produced and moderated by the End Brain Cancer Initiative (EBCI).
(Courtesy of ASCO FDA Alerts) tovorafenib FDA Approval for LGG On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. […]
